[HTML][HTML] National Marrow Donor Program–sponsored multicenter, phase II trial of HLA-mismatched unrelated donor bone marrow transplantation using post-transplant …
Journal of clinical oncology, 2021•ncbi.nlm.nih.gov
PURPOSE Hematopoietic cell transplantation (HCT) is curative for hematologic disorders,
but outcomes are historically inferior when using HLA-mismatched donors. Despite
unrelated donor registries listing> 38 million volunteers, 25%-80% of US patients lack an
HLA-matched unrelated donor, with significant disparity across ethnic groups. We
hypothesized that HCT with a mismatched unrelated donor (MMUD) using post-transplant
cyclophosphamide (PTCy), a novel strategy successful in overcoming genetic disparity …
but outcomes are historically inferior when using HLA-mismatched donors. Despite
unrelated donor registries listing> 38 million volunteers, 25%-80% of US patients lack an
HLA-matched unrelated donor, with significant disparity across ethnic groups. We
hypothesized that HCT with a mismatched unrelated donor (MMUD) using post-transplant
cyclophosphamide (PTCy), a novel strategy successful in overcoming genetic disparity …
Abstract
PURPOSE
Hematopoietic cell transplantation (HCT) is curative for hematologic disorders, but outcomes are historically inferior when using HLA-mismatched donors. Despite unrelated donor registries listing> 38 million volunteers, 25%-80% of US patients lack an HLA-matched unrelated donor, with significant disparity across ethnic groups. We hypothesized that HCT with a mismatched unrelated donor (MMUD) using post-transplant cyclophosphamide (PTCy), a novel strategy successful in overcoming genetic disparity using mismatched related donors, would be feasible and increase access to HCT.
ncbi.nlm.nih.gov
